Novartis Gene Therapies reported that interim data from the ongoing phase 3 STR1VE-EU clinical trial for Zolgensma showed patients with spinal muscular atrophy Type 1 continued to experience significant therapeutic benefit, including event-free survival, rapid and sustained improvement in motor function and motor milestone achievement. The company said nearly two-thirds of patients in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months. Two-thirds of patients were free of feeding support.
"These strong interim results from the STR1VE-EU clinical trial continue to demonstrate consistent and significant therapeutic benefit in patients with SMA Type 1, adding to the robust body of clinical evidence for Zolgensma," said Shephard Mpofu, SVP, Chief Medical Officer, Novartis Gene Therapies.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.